tetano
Editor, Senior Moderator
Nat Commun
. 2024 Apr 16;15(1):3284.
doi: 10.1038/s41467-024-47393-3. Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection
Chang Liu[SUP] #[/SUP][SUP] 1 2 [/SUP], Raksha Das[SUP] #[/SUP][SUP] 2 [/SUP], Aiste Dijokaite-Guraliuc[SUP] #[/SUP][SUP] 2 [/SUP], Daming Zhou[SUP] #[/SUP][SUP] 1 3 4 [/SUP], Alexander J Mentzer[SUP] 2 5 [/SUP], Piyada Supasa[SUP] 2 [/SUP], Muneeswaran Selvaraj[SUP] 2 [/SUP], Helen M E Duyvesteyn[SUP] 3 [/SUP], Thomas G Ritter[SUP] 5 [/SUP], Nigel Temperton[SUP] 6 [/SUP], Paul Klenerman[SUP] 5 7 8 9 [/SUP], Susanna J Dunachie[SUP] 5 7 10 11 [/SUP], Neil G Paterson[SUP] 12 [/SUP], Mark A Williams[SUP] 12 [/SUP], David R Hall[SUP] 12 [/SUP], Elizabeth E Fry[SUP] 13 [/SUP], Juthathip Mongkolsapaya[SUP] 14 15 16 [/SUP], Jingshan Ren[SUP] 17 [/SUP], David I Stuart[SUP] 18 19 20 [/SUP], Gavin R Screaton[SUP] 21 22 [/SUP]
Affiliations
The rapid evolution of SARS-CoV-2 is driven in part by a need to evade the antibody response in the face of high levels of immunity. Here, we isolate spike (S) binding monoclonal antibodies (mAbs) from vaccinees who suffered vaccine break-through infections with Omicron sub lineages BA.4 or BA.5. Twenty eight potent antibodies are isolated and characterised functionally, and in some cases structurally. Since the emergence of BA.4/5, SARS-CoV-2 has continued to accrue mutations in the S protein, to understand this we characterize neutralization of a large panel of variants and demonstrate a steady attrition of neutralization by the panel of BA.4/5 mAbs culminating in total loss of function with recent XBB.1.5.70 variants containing the so-called 'FLip' mutations at positions 455 and 456. Interestingly, activity of some mAbs is regained on the recently reported variant BA.2.86.
. 2024 Apr 16;15(1):3284.
doi: 10.1038/s41467-024-47393-3. Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection
Chang Liu[SUP] #[/SUP][SUP] 1 2 [/SUP], Raksha Das[SUP] #[/SUP][SUP] 2 [/SUP], Aiste Dijokaite-Guraliuc[SUP] #[/SUP][SUP] 2 [/SUP], Daming Zhou[SUP] #[/SUP][SUP] 1 3 4 [/SUP], Alexander J Mentzer[SUP] 2 5 [/SUP], Piyada Supasa[SUP] 2 [/SUP], Muneeswaran Selvaraj[SUP] 2 [/SUP], Helen M E Duyvesteyn[SUP] 3 [/SUP], Thomas G Ritter[SUP] 5 [/SUP], Nigel Temperton[SUP] 6 [/SUP], Paul Klenerman[SUP] 5 7 8 9 [/SUP], Susanna J Dunachie[SUP] 5 7 10 11 [/SUP], Neil G Paterson[SUP] 12 [/SUP], Mark A Williams[SUP] 12 [/SUP], David R Hall[SUP] 12 [/SUP], Elizabeth E Fry[SUP] 13 [/SUP], Juthathip Mongkolsapaya[SUP] 14 15 16 [/SUP], Jingshan Ren[SUP] 17 [/SUP], David I Stuart[SUP] 18 19 20 [/SUP], Gavin R Screaton[SUP] 21 22 [/SUP]
Affiliations
- PMID: 38627386
- PMCID: PMC11021415
- DOI: 10.1038/s41467-024-47393-3
The rapid evolution of SARS-CoV-2 is driven in part by a need to evade the antibody response in the face of high levels of immunity. Here, we isolate spike (S) binding monoclonal antibodies (mAbs) from vaccinees who suffered vaccine break-through infections with Omicron sub lineages BA.4 or BA.5. Twenty eight potent antibodies are isolated and characterised functionally, and in some cases structurally. Since the emergence of BA.4/5, SARS-CoV-2 has continued to accrue mutations in the S protein, to understand this we characterize neutralization of a large panel of variants and demonstrate a steady attrition of neutralization by the panel of BA.4/5 mAbs culminating in total loss of function with recent XBB.1.5.70 variants containing the so-called 'FLip' mutations at positions 455 and 456. Interestingly, activity of some mAbs is regained on the recently reported variant BA.2.86.